HEALTHSEMAFOR
Chinese drug reduces lung cancer death risk by 34% in trial
A Chinese lung cancer drug reduced the risk of death by 34% in a late-stage trial, extending survival by four months when combined with chemotherapy for squamous non-small-cell lung cancer. The results highlight China's growing pharmaceutical innovation, alongside global advancements like Eli Lilly's obesity drug and a pancreatic cancer treatment.
Mentioned
Related Signal
Adjacent reporting
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
- Vision problem leads to man's stage 4 lung cancer diagnosis, new drug extends survival
- WATCH: How a new drug could lengthen lives of pancreatic cancer patients
- Drugs that boost immunity are making lung cancer less deadly
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer